Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$338.91 USD
+5.52 (1.66%)
Updated Jan 10, 2025 04:00 PM ET
After-Market: $338.72 -0.19 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDGL 338.91 +5.52(1.66%)
Will MDGL be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Other News for MDGL
RTW INVESTMENTS, LP Acquires Additional Shares in Allurion Technologies Inc
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
SA Asks: Which biotechs are most likely to be acquired near-term?
Madrigal Pharmaceuticals Inc (MDGL) to Present at J.P. Morgan Healthcare Conference
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc